Web Date: January 25, 2016
Industry, Academia Join For U.K. Drug Development Fund
AstraZeneca, GlaxoSmithKline, Johnson & Johnson and three U.K. universities—Imperial College London, University of Cambridge and University College London (UCL)—are combining to create an almost-$60 million investment fund for drug development.
The program, the Apollo Therapeutics Fund, aims to accelerate the translation of academic science into medicines. The partners plan to develop drugs for all therapy areas using systems including small molecules, peptides, proteins, antibodies, and cell and gene therapies.
The industrial partners will contribute close . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society